Drug
CC 97540
CC 97540: highest development phase Phase 2, developed by Bristol-Myers Squibb. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bristol-Myers Squibb
Trials
| Drug | Phase | Indication |
|---|---|---|
| CC-97540 NCT07015983 | Phase 2 | Lupus Erythematosus, Systemic |
| CC-97540 NCT07388277 | Phase 1/2 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis |
Latest
No recent events.
Follow CC 97540 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.